Reference Detail

Ref Type

abstract

PMID

Authors

G. Shapiro J.E. Ang E. Castanon Alvarez A.I. Spira P. Cassier P. Lorusso S. Gaillard H.A. Chen S. Kummar M.G. Krebs R. Plummer E. Carcereny E. Meshoulam Nikolaeva J. Munck D. Chan M. Dijkstra H.N. Keer E.K. Lee

Title

791P Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway

Journal	Vol	Issue	Date	Pages	Journal Short Title
Annals of Oncology	35	Supplement 2	2024

URL

https://www.annalsofoncology.org/article/S0923-7534(24)03670-6/fulltext

Abstract Text

Background ASTX029 is an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor which both prevents phosphorylation of ERK and directly inhibits ERK kinase activity. MAPK pathway genomic alterations are common in gynecological (GYN) malignancies. Here we report on the GYN cohort of an open-label Phase 2 study of ASTX029 in subjects with relapsed/refractory solid tumors (NCT03520075). Methods The primary objective was objective response rate (ORR) by RECIST v1.1. Subjects with relapsed/refractory GYN solid tumors with MAPK pathway genomic alterations were eligible. ASTX029 was administered continuously in 21-day cycles (once daily oral dosing at 200 mg). Results Thirty-two subjects were treated (mean age 64 years; 15 ovarian, 13 endometrial, 1 cervical, and 3 other). As of 05Apr2024, the only grade ≥3 AE assessed as related to ASTX029 in ≥5% of subjects was anemia (n=3; 9.4%); no SAEs (of 12; 38%) or deaths were related to ASTX029. Related grade 2 AEs in ≥5% of subjects included anemia (n=6; 19%), blurred vision (n=2; 6%), diarrhoea (n=6; 19%), nausea (n=4; 13%), fatigue (n=4; 13%), ejection fraction decreased (n=2; 6%), decreased appetite (n=2; 6%), and rash maculo-papular (n=2; 6%). Six subjects (18.8%) interrupted treatment due to a related AE but none permanently discontinued treatment for this reason. The most frequent reason for treatment discontinuation was progressive disease (n=27; 84.4%). PK exposures were in the pharmacologically active range with mean cycle 1 AUC0-24 as 10321 ng*hr/mL (76%CV) and Cmax as 3457 ng/mL (160%CV), n=11. Four subjects had a PR including: NRASQ61K ovarian adenocarcinoma who progressed on prior MEKi treatment (14+ cycles), KRASG12V cervical (mesonephric) adenocarcinoma (17+ cycles), KRASG12D endometrioid ovarian (11 cycles), and KRASG12D endometrioid endometrial (8 cycles). ORR (CR+PR) was 12.5% (% 95% CI, 1.0-24.0). Median overall survival was 11.2 months (95% CI, 8.4-NE); median duration of response was 8.5 months (95% CI, 3.4-11.1). Median follow-up on study was 7.7 months (95% CI, 5.6-13.9). Conclusions ASTX029 was well-tolerated and induced PR in four subjects (ORR of 12.5%). The response following MEKi therapy suggests further study in this population is warranted. Clinical trial identification NCT03520075.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NRAS Q61K	ovary adenocarcinoma	predicted - sensitive	ASTX029	Case Reports/Case Series	Actionable	In a Phase II trial, ASTX029 treatment was well tolerated in patients with relapsed/refractory gynecological tumors harboring MAPK pathway alterations, and resulted in an objective response rate of 12.5% (4/32, all partial responses), a median duration of response of 8.5 months, and a median overall survival of 11.2 months, with a partial response in a patient with ovarian adenocarcinoma harboring NRAS Q61K who progressed on prior MEKi therapy (Ann Oncol (2024) 35 (Suppl_2): S591; NCT03520075).	detail...